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Safety and clinical activity of elosulfase alfa in
pediatric patients with Morquio A syndrome
(mucopolysaccharidosis IVA) less than 5 y
Simon A. Jones1, Martin Bialer2, Rossella Parini3, Ken Martin4, Hui Wang4, Ke Yang4, Adam J. Shaywitz4 and Paul Harmatz5

Background: Previous studies have shown that elosulfase
alfa has a favorable efficacy/safety profile in Morquio A patients
aged ≥5 y. This study evaluated safety and impact on urine
keratan sulfate (uKS) levels and growth velocity in younger
patients.
Methods: Fifteen Morquio A patients aged <5 y received
elosulfase alfa 2.0 mg/kg/week for 52 wk during the primary
treatment phase of a phase II, open-label, multinational study.
Primary endpoint was safety and tolerability; secondary endpoints were change in uKS and growth velocity over 52 wk.
Results: All 15 patients completed the primary treatment
phase. Six of 743 infusions (0.8%) administered led to adverse
events (AEs) requiring infusion interruption and medical intervention. Eleven patients (73.3%) had ≥1 study drug-related AE,
mostly infusion-associated reactions. Mean z-score growth
rate per year numerically improved from −0.6 at baseline to
−0.4 at week 52. Comparison to untreated subjects of similar age in the Morquio A Clinical Assessment Program study
showed a smaller decrease in height z-scores for treated than
for untreated patients. Mean percent change from baseline in
uKS was −30.2% at 2 wk and −43.5% at 52 wk.
Conclusion: Early intervention with elosulfase alfa is welltolerated and produces a decrease in uKS and a trend toward
improvement in growth.

M

orquio A syndrome is a rare inherited disorder caused
by mutations of the gene that codes for the lysosomal
enzyme N-acetylgalactosamine-6-sulfatase (GALNS, EC
3.1.6.4), which degrades the glycosaminoglycans keratan sulfate (KS) and chondroitin sulfate (1,2). GALNS insufficiency
leads to progressive accumulation of glycosaminoglycans in
multiple tissues and organs. In turn, this accumulation leads
to significant morbidities and multisystemic clinical impairments causing diminished functional capacity, decreased
endurance, impaired quality of life, and early mortality (3). The
most apparent and most commonly reported clinical features
of patients with Morquio A syndrome are progressive skeletal

dysplasia and musculoskeletal abnormalities, typically associated with disproportionate short stature, short neck and trunk,
and joint abnormalities (3–5). Although growth impairment
is a major manifestation of Morquio A syndrome, growth is
generally normal in very young patients and starts to decrease
between the ages of 2 and 5 y, resulting in a mean adult standing height around 120 cm in men and 110 cm in women (4,6,7).
Morquio A patients also commonly present with nonskeletal
manifestations such as respiratory dysfunction, cardiovascular abnormalities, cervical/thoracolumbar cord compression,
vision and hearing impairment, dental abnormalities, and
hepatosplenomegaly (3,5).
In 2014, recombinant human GALNS (elosulfase alfa,
Vimizim; BioMarin Pharmaceutical, Novato) was approved as
an enzyme replacement therapy (ERT) for patients with Morquio
A syndrome in the United States, Europe, Canada, Australia,
and Brazil (8) (http://investors.bmrn.com/releases.cfm). The
pivotal randomized, double-blind, placebo-controlled phase III
study showed significant improvement in the 6-min walk test
distance (primary endpoint), a substantial reduction in urine
KS (uKS), and numerical improvements in several exploratory
endpoints, including respiratory function, height, and growth
rate, with 2 mg/kg/week elosulfase alfa dosing (9,10). However,
the phase III study, as well as a previous phase I/II dose-ranging
study, only included patients of 5 y of age and older (9,11). This
open-label study was designed to explore the safety and clinical
activity of elosulfase alfa in Morquio A patients younger than
5 y of age. Growth was selected as the major clinical endpoint
of the study in order to assess if elosulfase alfa could prevent
or minimize the deviation from the normal growth curve that
generally occurs during these early years.
RESULTS
Patient Characteristics

Fifteen patients aged 9 mo to 4.9 y were enrolled in the study.
All patients completed the primary treatment phase, and
none permanently discontinued elosulfase alfa. Demographic
and baseline data are presented in Table 1. Based on physical
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examination findings at screening and reported medical history, the majority of patients had abnormal musculoskeletal
features (93.3%), with knee deformities (66.7%), pectus carinatum (66.7%), kyphosis (60.0%), and dysmorphism (60%)
most frequently reported. Other findings were abnormal general appearance (60.0%), abnormal head, eyes, ears, nose, and
throat (66.7%), corneal opacity (clouding) (33.3%), and deafness (53.3%). Cardiovascular abnormalities occurred in three
(20%) patients and included mild to moderate mitral, pulmonary, and/or tricuspid valve regurgitation and mitral and/or
aortic valve thickening. Standing height (in patients ≥ 2 y) was
severely affected, with almost half of patients (46.7%) below
the third percentile of normal for age. Normalized uKS (mean
35.9 μg/mg creatinine; Table 1) was elevated tenfold above the
mean for a similar age control population (12).
Table 1. Demographics and baseline characteristics
Characteristics

Elosulfase 2.0 mg/
kg/wk (N = 15)

Age at enrollment (y)
Mean (SD)

3.1 (1.3)

Median

3.1

Min, Max

0.8, 4.9

Age group (y), N (%)
0 to < 3 y

7 (46.7)

≥ 3 to < 5 y

8 (53.3)

Sex, N (%)
Female

8 (53.3)

Male

7 (46.7)

Race, N (%)
Asian

4 (26.7)

White

10 (66.7)

Other: East Asian/African American

1 (6.7)

Ethnicity, N (%)
Hispanic or Latino
Not Hispanic or Latino

1 (6.7)
14 (93.3)

Normalized uKSa (μg/mg)
Mean (SD)

35.9 (12.3)

Median

35.4

Min, Max

18.8, 56.5

Length (cm)
Mean (SD)

90.1 (9.3)

Median

89.6

Min, Max

75.8, 113.0

Standing heightb (cm)
Mean (SD)

88.9 (9.0)

Median

90.0

Min, Max

72.3, 109.2

Normalized urine keratan sulfate (uKS) is calculated as urine KS divided by urine creatinine.
Normalized uKS level in healthy controls aged 0-6 y range between 0.42 and 5.7 µg/mg
creatinine (12). bHeight was not obtained for two of the subjects who were < 2 y of age.

a
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Safety Results

All 15 enrolled patients were included in the safety analysis and
completed 52 wk of treatment. The mean weekly dose received
was 1.9 (±0.1) mg/kg/patient. Of 780 planned infusions, 37
(4.7%) were missed in 12 (80.0%) patients. All patients had
≥88% dosing compliance (100 × (actual dose/total planned
dose)).
Table 2 summarizes the AEs reported during the 52 wk
study. All 15 patients reported at least one AE. Eleven (73.3%)
patients experienced at least one study drug-related AE. The
most frequently reported drug-related AEs were pyrexia
(40.0%) and vomiting (33.3%) (Table 2). Most AEs were mild
or moderate in severity. Only one patient experienced severe
events, i.e., routine tonsillectomy for enlarged tonsils and
cervical cord compression, which was unrelated to the tonsillectomy. Both events were not considered drug-related by the
investigator. None of the children discontinued from the study
due to AEs.
All 15 patients reported at least one infusion-associated reaction (IAR) (any AE occurring after infusion onset and within
1 d after infusion end, regardless of relation with study drug).
All IARs were mild or moderate in severity and generally manageable with symptomatic treatment. Six of the 743 infusions
(0.8%) were interrupted (three infusions) or discontinued
Table 2. Overall summary of AEs
Elosulfase alfa 2.0 mg/
kg/wk (N = 15)
Any AE

15 (100.0%)
1 (6.7%)

Grade 3
Number of AE per subject: mean/median
Any study drug-relateda AE

27.7/25.0
11 (73.3%)
0 (0.0%)

Grade 3
Most frequently reported drug-related AEs
b

a

Pyrexia

6 (40.0%)

Vomiting

5 (33.3%)

Abdominal pain

3 (30%)

Abdominal pain upper

3 (30%)

Tachycardia

3 (30%)

Any SAE

4 (26.7%)
1 (6.7%)

Grade 3
Any study drug-relateda SAE

1 (6.7%)
0 (0.0%)

Grade 3
Any AE leading to study discontinuation

0 (0.0%)

Any AE leading to permanent study
drug discontinuation

0 (0.0%)

Death

0 (0.0%)

AEs coded by MedDRA version 15.0; maximum severity is summarized by subject.
Severity based on CTCAE: grade 1 = mild; 2 = moderate; 3 = severe, disabling or limiting
self care activities of daily living; 4 = life-threatening or debilitating; 5 = Death.
All AEs are treatment-emergent; subjects with more than one AE within a category
were counted once.
AE, adverse event.
a
A drug-related AE was classified by investigator as possibly or probably related to study
drug. bOccurring in at least three patients (20%).
Official journal of the International Pediatric Research Foundation, Inc.
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Figure 1. Normalized urine keratan sulfate (uKS): mean percent change from baseline (N = 15). Normalized uKS is calculated as uKS divided by urine
creatinine.

(three infusions) due to an AE and required medical intervention in three patients (20%). AEs that resulted in infusion
interruptions and/or discontinuations could be managed with
symptomatic treatment (oxygen, IV steroids, IV antihistamines, or IV fluids) and infusion rate adjustment. In all cases,
patients were successfully redosed and tolerated subsequent
infusions.
There were no life-threatening AEs (grade 4) or deaths.
Four patients (26.7%) reported a total of eight serious AEs
(SAEs), with only one assessed as related to the study drug.
Supplementary Appendix S1 online provides more details
about this SAE. Eight hypersensitivity AEs occurred in four
(26.7%) patients (more details are provided in Supplementary
Appendix S1 online).
No clinically meaningful changes in vital signs, electrocardiograms, echocardiograms, clinical chemistry, hematology,
or urinalysis results were observed. No new or unexpected
safety signals were observed and no expedited safety reports
were required.
Elosulfase alfa total antibodies were detected in all patients by
week 4 and remained positive throughout the study. No patients
tested positive for drug-specific IgE. The number of patients
with hypersensitivity AEs was too low to identify a relationship
with total antibody titers. No apparent relationship was observed
between total antibody titers and height z-score measurements.
Reductions in uKS occurred and were maintained despite the
development of antidrug antibodies. Patients with total antibody titers greater than the mean had similar decreases in uKS
as patients with total antibody titers below the mean.
Efficacy Results

All 15 patients were included in the efficacy analyses. Elosulfase
alfa substantially decreased the mean normalized uKS levels
within 2 wk, which was maintained over 52 wk (Figure 1). The
mean (±SD) percent change from baseline in uKS was −30.2%
(±12.7) at 2 wk and −43.5% (±22.2) at 52 wk.

Official journal of the International Pediatric Research Foundation, Inc.

The mean weight (all patients) increased by 1.7 (±0.8) kg
from baseline to week 52; a mean percent change of 13.8%
(±7.3). The mean height in patients ≥2 y of age (N = 12)
increased by 5.3 (±2.4) cm from baseline to week 52; a mean
percent change of 5.9% (±2.5). In patients <2 y (N = 3), the
mean length increased by 6.0 (±2.7) cm from baseline to week
52; a mean percent change of 6.8% (±3.3). For all 15 patients,
the mean height/length for age z-score was −1.6 (±1.6) at baseline and −1.9 (±1.6) after 52 wk of treatment (Figure 2a). The
mean change from baseline at 52 wk was −0.4 (±0.5). The mean
height z-score for the 12 patients ≥2 y of age at baseline was
−2.0 (±1.5), as compared to −2.2 (±1.3) in 24 untreated subjects of similar age from the Morquio A Clinical Assessment
Program (MorCAP) natural history study (1 of the 25 patients
from the MorCAP study did not have a week 52 assessment).
After 52 wk, height z-scores in both groups were −2.2 (±1.7)
and −3.0 (±1.2), respectively (Figure 2b).
The mean growth rate z-score per year was −0.6 (± 0.6; N = 8)
at baseline and −0.4 (±0.5; N = 15) at week 52. Cumulative
growth rate change was computed for the eight patients for
whom prestudy growth rate data were available. The mean
change in growth rate from baseline to week 52 in these patients
was 0.2 (±1.0) (Figure 2c). In patients ≥2 y of age, the mean
normalized growth rate z-score was −0.8 (±0.8; N = 5) at baseline and −0.3 (±0.5; N = 12) at week 52. Mean change in the
patients with prestudy growth rate data was 0.6 (±1.1; N = 5).
DISCUSSION
Elosulfase alfa is currently the only approved drug therapy
for Morquio A syndrome that directly targets the underlying
cause of the disease. Previous studies have assessed the efficacy and safety of elosulfase alfa in a wide age range, but not in
patients younger than 5 y (9–11). The present study is the first
to specifically examine the safety, tolerability, and pharmacodynamic responses, as demonstrated by reduction of uKS, and
impact on growth of elosulfase alfa in this young patient group.
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Figure 2. Normalized height/length and growth rate from baseline to
week 52. (a) Mean standing height/lengtha z-score. Normalized standing
height or length was computed using Centers for Disease Control normal
values (17). (b) Mean standing height z-score at baseline and 52 wk for
12 patients ≥2 y of age included in this study (upper line) compared with
25 untreated subjects of 2–5 y of age included in the Morquio A Clinical
Assessment Program (MorCAP) longitudinal natural history study at baseline and 52 wk (lower line). One of the 24 patients from the MorCAP study
did not have a week 52 assessment and was excluded from this analysis.
(c) Mean growth rate (per year) for standing height/lengtha z-score.
Baseline rate calculation was based on observations up to 2 y prior to
study entry. aLength was measured instead of standing height in subjects
<2 y of age (N = 3).

Overall, the safety analysis of this study showed that administration of elosulfase alfa is generally well tolerated in patients
aged <5 y. The study did not reveal any new unexpected safety
issues that were not reported in previous studies including older
patients (9–11). Overall dosing compliance was high, i.e., ≥88%
for all patients, with only 37 of 780 infusions missed (< 5%).
720 Pediatric Research      Volume 78 | Number 6 | December 2015

No patients permanently discontinued treatment due to an AE
and infusions requiring interruption or discontinuation due to
an AE and requiring medical intervention, such as IV antihistamines or IV steroids, represented a small percentage of all
743 infusions (0.8%). This is comparable to the phase III study
with 1.3% of infusions interrupted or discontinued (9). Only
one patient experienced a SAE that was considered related to
elosulfase alfa (moderate hypersensitivity). This patient continued to receive subsequent infusions and completed the 52 wk
of treatment without experiencing additional hypersensitivity
events. All patients experienced at least one IAR, but these were
mild to moderate in severity and generally manageable with
symptomatic treatment. The most frequently reported drugrelated AEs (pyrexia, vomiting) were also IARs, similar to what
was observed in the pivotal phase III study (9). Headache and
nausea were less frequent in this study than in the phase III
study (9). This may be related to the need to have appropriate
language skills to verbalize and convey nausea and headache
symptoms. Although all patients developed antidrug total antibodies by week 4, there was no apparent relationship between
total antibody titers and uKS or height z-score measurements.
The same has been reported for older patients included in the
phase III study (9). Although promising, the favorable tolerability and safety data in this pediatric patient population should
be interpreted cautiously due to certain limitations in the study
design, including the open-label design and the limited sample
size.
The efficacy analysis showed a substantial decrease in mean
normalized uKS levels within 2 wk of treatment with elosulfase
alfa, with the decreased levels being maintained over 52 wk.
uKS is considered a pharmacodynamic biomarker for Morquio
A syndrome with higher levels of uKS being associated with
more severe clinical impairment (4,13). The observed decline
in uKS of 43.5% was comparable to that reported for older
children and adult patients in the elosulfase alfa phase I/II and
phase III studies (9,11).
Skeletal abnormalities represent a major manifestation of
Morquio A syndrome; however, young patients often do not
possess, or have not yet developed, the severe abnormalities
present in older patients. It is therefore postulated that early
treatment may be particularly effective in changing the course of
skeletal disease (4,6,7). Although there is currently limited data
on younger patients, available data from natural history studies
show that patients gradually fall off the anticipated growth trajectory by 2 y of age (4,6,7). In MorCAP, a natural history study
including 325 untreated patients with Morquio A syndrome,
height z-scores in patients older than 5 y were approximately
5–7 SDs below the normal range, while in younger patients,
height was already decreasing by about 2 SDs below normal
(4). These findings are consistent with the results of the current
study in which the baseline mean normalized standing height
z-score was −1.6. After 1 y of treatment, the mean z-score was
only slightly lower (−1.9) and the mean normalized growth
rate z-scores were numerically improved from baseline, indicating a closer to normal growth rate on treatment. Impact of
treatment on growth may be more appropriately evaluated if
Official journal of the International Pediatric Research Foundation, Inc.
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disease-specific growth charts were used as they are currently
available for other MPS disorders (14,15). Comparison of the
current data with longitudinal growth data from the MorCAP
study suggests that elosulfase alfa improves growth rates
(Figure 2b). This finding is consistent with that of the phase III
study where results suggested improved growth with treatment
in individuals still growing (females <15 y and males <18 y)
(10). However, as growth rates vary considerably during these
years, a longer duration of follow-up will be needed to determine the significance of this early observation (16).
Corneal clouding, hearing loss/deafness, and cardiac valve
abnormalities were common findings in the study population, even in the younger children. The prevalence of these
findings was strikingly similar to that reported previously
in the pediatric patients included in the MorCAP study (4),
which highlights the importance of regular follow-up and the
need for and potential benefit of early intervention. It should
be noted that the effect of early ERT on corneal clouding
and cardiac valves is unclear due to the poor vascularity at
these sites, and based on the experience with ERT in other
mucopolysaccharidoses.
In conclusion, the results of this study suggest a favorable
benefit/risk profile for elosulfase alfa in pediatric Morquio A
patients less than 5 y of age. Early intervention with elosulfase
alfa produced a decrease in urinary KS and seemed to have
improved growth. The extension phase of this study will provide more comprehensive data on growth effects and other
long-term benefits in these patients.
METHODS

Study Design
This study is an ongoing, phase II, open-label, multinational study
consisting of an initial 52-wk primary treatment phase and an extension period of up to 156 wk plus 1 additional week for final study
assessments. We report the results of the completed primary treatment phase, of which the primary objective was to evaluate safety and
tolerability of infusions of elosulfase alfa 2.0 mg/kg/week in Morquio
A patients <5 y of age. The secondary objectives were to evaluate its
ability to reduce uKS levels and to assess its impact on growth velocity. The dose of 2.0 mg/kg/week was selected from the analysis of
study data from a phase I/II dose escalation study (11).
The study is being conducted by four investigators at four study
centers in three countries (USA, UK, and Italy) in accordance with
the United States Code of Federal Regulations and/or other national
and local regulations, the ICH Harmonized Tripartite Guideline
(Guideline for Good Clinical Practice E6) and the ethical principles
established by the Declaration of Helsinki.
Patient Selection
Individuals eligible to participate in this study were <5 y of age at
first infusion, had a documented clinical diagnosis of Morquio A
syndrome based on reduced fibroblast or leukocyte GALNS enzyme
activity or genetic testing confirming the diagnosis. Each patient’s
parent or other legally authorized representative provided written
informed consent before study onset. Exclusion criteria were previous
hematopoietic stem cell transplantation or treatment with elosulfase
alfa, known hypersensitivity to any of the components of elosulfase
alfa, major surgery within 3 mo prior to study entry or planned major
surgery during the initial treatment period, use of any investigational product or investigational medical device within 30 d prior to
screening or requirement for any investigational agent prior to study
completion, concurrent disease or condition that would interfere with
Official journal of the International Pediatric Research Foundation, Inc.
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study participation or safety (symptomatic cervical spine instability,
clinically significant spinal cord compression, severe cardiac disease),
and any condition that placed the patient at high risk of poor treatment compliance or of not completing the study.
Study Drug Administration
All patients received pretreatment with an antihistamine within 1 h
prior to each infusion. The choice of preinfusion medications was
left to the discretion of the investigator. There was some minimal
instruction to try nonsedating antihistamines first. Elosulfase alfa
was diluted with sterile 0.9% sodium chloride (no standard source)
at room temperature prior to administration and was infused IV over
approximately 4 h, with vital signs monitored before, during, and after
the infusion. Patients were also monitored by continuous pulse oximetry during and for at least 60 min after the infusion. Supplementary
Appendix S2 online provides more detailed infusion procedures.
Safety Evaluation
Supplementary Appendix S3 online provides a schedule of the most
important safety and efficacy assessments done during the primary
treatment phase. Safety was assessed by examining incidence, severity,
and relationship to study drug of treatment-emergent adverse events
reported during the study. A treatment-emergent adverse event was
defined as any adverse event (AE) that was new, increased in frequency,
or worsened in severity after the first dose of study drug, including
AEs with missing onset dates. An AE assessed by the investigator as
possibly or probably related to study drug documented in the electronic case report form was counted as drug-related. In addition, vital
signs, physical examinations, laboratory results, electrocardiograms,
echocardiograms, cervical spine radiographs, concomitant medications, and immunogenicity were assessed per protocol. Machine types
for making electrocardiograms and radiographs were not specified
and varied from center to center, but a full set of instructions on how
to collect the images was provided by BioClinica (Newtown, PA).
The investigator determined the severity of each event using the
National Cancer Institute Common Terminology Criteria for Adverse
Events v. 4.0. Hypersensitivity AEs were identified by utilizing the
broad algorithmic Anaphylactic Reaction Standardized MedDRA
Query (SMQ) v. 15.0 and the broad Angioedema SMQ. IARs were
defined as all AEs (regardless of drug relationship) that occurred after
infusion onset and within 1 d after infusion end.
Immunogenicity tests were performed using validated immunogenicity assays on blood samples and included a total antidrug antibody
test (BioMarin Pharmaceutical), and drug-specific (anti-rhGALNS)
IgE and total IgE tests (Viracor-IBT Laboratories, Lee’s Summit, MO).
Efficacy Evaluation
uKS levels (normalized to creatinine) were measured by liquid chromatography followed by tandem mass spectrometry (Pacific BioLabs,
Hercules, CA) (see Supplementary Appendix S3 online for schedule
of assessments) (12). Normalized standing height or length was computed using the Centers for Disease Control norms (see Supplementary
Appendix S4 online for details on method) (17). Growth rate change was
calculated as on-study growth rate (GR1S)–prestudy growth rate (GR0) for
patients who had growth measurements within 2 y prior to study entry,
with GR0 = (Zbaseline − Zprestudy)/T and GR1S = (ZS − Zbaseline)/T; where Zbaseline
is the standing height/length z-score measured at baseline, Zprestudy the
z-score closest to, but not greater than, 2 y prior to study entry, ZS the
z-score measured at weeks 13, 26, 39, and 52, and T the time (in years)
between corresponding measurements. All anthropometric measurements and growth rates were analyzed among all patients and for the
subset of patients ≥2 y of age. Finally, mean height z-scores of the patients
aged ≥2 y (Centers for Disease Control height measurements start at 2 y
vs. length below this age) were compared to those of 25 untreated patients
included in the MorCAP natural history study (4). These untreated
patients were of similar age (2–5 y old) at baseline and at 52 wk. Baseline
age, height, weight, and distribution of gender were similar between
treated and untreated groups (Supplementary Appendix S5 online).
Statistical Methods
This paper reports the results of the completed 52-wk primary treatment phase. Safety and tolerability of elosulfase alfa was the primary
Volume 78 | Number 6 | December 2015      Pediatric Research
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endpoint. Secondary endpoints were change in uKS and growth
velocity over 52 wk. The efficacy population consisted of all patients
who received ≥1 dose of study drug and had ≥1 postbaseline efficacy
measurement. The safety population consisted of all patients who
received any study drug throughout the study duration. Compliance
was derived from the total amount of study drug intake (actual dose)
divided by the planned study drug intake during the study period
(total planned dose), and multiplied by 100%.
Descriptive statistical summaries of continuous variables were
done using SAS (r) Proprietary Software 9.2 (TS2M0) (SAS Institute,
Cary, NC) and included the mean, SD, median, and range. Descriptive
summaries of categorical variables included sample size and percent.
Z-score height/length was compared to 25 patients of MorCAP who
were aged 2–5 at entry to the MorCAP study. Patients in MorCAP had
annual anthropometric assessments; however, there was some variability around the timing of the visit and the first annual follow-up
score was linearly interpolated to precisely 365 d postbaseline.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/pr
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